Correction
31 July 2017
Reply
Gonzalo Sapisochin, Jordi Bruix – 31 July 2017
The selective peroxisome proliferator–activated receptor‐delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice
Fahrettin Haczeyni, Hans Wang, Vanessa Barn, Auvro R. Mridha, Matthew M. Yeh, W. Geoffrey Haigh, George N. Ioannou, Yun‐Jung Choi, Charles A. McWherter, Narcissus C.‐H. Teoh, Geoffrey C. Farrell – 31 July 2017 – Lipotoxicity associated with insulin resistance is central to nonalcoholic steatohepatitis (NASH) pathogenesis. To date, only weight loss fully reverses NASH pathology, but mixed peroxisome proliferator–activated receptor‐alpha/delta (PPAR‐α/δ) agonists show some efficacy. Seladelpar (MBX‐8025), a selective PPAR‐δ agonist, improves atherogenic dyslipidemia.
Intrahepatic cholangiocarcinoma arising from HBV infection may be a highly selected population for liver transplantation
Jinyang Gu, Seogsong Jeong, Qiang Xia – 31 July 2017
Correction
31 July 2017
Characteristics of hepatic insulin‐sensitive nonalcoholic fatty liver disease
Fumika Shigiyama, Naoki Kumashiro, Yasuhiko Furukawa, Takashi Funayama, Kageumi Takeno, Noritaka Wakui, Takashi Ikehara, Hidenari Nagai, Hikari Taka, Tsutomu Fujimura, Hiroshi Uchino, Yoshifumi Tamura, Hirotaka Watada, Tetsuo Nemoto, Nobuyuki Shiraga, Yasukiyo Sumino, Takahisa Hirose – 29 July 2017 – Nonalcoholic fatty liver disease (NAFLD) plays a crucial role in type 2 diabetes and hepatocellular carcinoma. The major underlying pathogenesis is hepatic insulin resistance.
Reply
Carlos Moctezuma‐Velazquez, Sylvia Kalainy, Juan G. Abraldes – 28 July 2017
Improving outcomes for transplantation of critically ill patients with cirrhosis?
William Bernal – 28 July 2017
Dendritic cells in hepatitis and liver transplantation
Radika Soysa, Xia Wu, I. Nicholas Crispe – 28 July 2017 – Dendritic cells (DCs) play a key role in innate immune responses and are also the most effective cells for the activation of T cell immunity. They acquire antigen and process it; then they display it on the cell surface bound in a noncovalent complex with human leukocyte antigen molecules of class I (human leukocyte antigens A, B, and C) and class II (human leukocyte antigen DR).
Management of portal hypertension before and after liver transplantation
Lukas W. Unger, Gabriela A. Berlakovich, Michael Trauner, Thomas Reiberger – 28 July 2017 – Orthotopic liver transplantation (OLT) represents a curative treatment option for end‐stage liver disease (ESLD). Although epidemiology of ESLD has recently changed due to the rising prevalence of nonalcoholic fatty liver disease and the decreased burden of hepatitis C virus infections due to highly effective antiviral regimens, the management of portal hypertension (PHT) remains a clinical challenge in the pre‐ and post‐OLT setting.